TY - JOUR
T1 - Advanced detection of recent changing trends in gastric cancer survival
T2 - Up-to-date comparison by period analysis
AU - Kim, Hyo Song
AU - Lee, Hyunkyoung
AU - Jeung, Hei Chul
AU - Noh, Sung Hoon
AU - Chung, Hyun Cheol
AU - Roh, Jae Kyung
AU - Nam, Chung Mo
AU - Rha, Sun Young
PY - 2011/12
Y1 - 2011/12
N2 - Objective: To establish a comprehensive cancer treatment and prevention policy, data collection should be performed in a timely manner, and survival analysis needs to reflect changes in treatment strategy. Therefore, we introduced the concept of period analysis for gastric cancer, the most prevalent cancer in Korea. We estimated 5- and 10-year survival trend of gastric cancer, based on data from the Yonsei Cancer Center Tumor Registry between 1990 and 2004. Methods: We compared the differences in survival between cohort, complete and period analyses for two different periods, 1995-99 and 2000-04. Results: A total of 11 724 cases were included. The median age of cancer diagnosis gradually increased over time, and more patients were diagnosed with Stage I disease in recent years. In the basic comparison of three estimated analytic methods (cohort, complete and period), period analysis (45.8%) was most similar to the actual 5-year observed survival rate (48.5%), when compared with cohort (43.6%) and complete (44.8%) analyses. When we compared survival between different 10-year periods (1990-99 and 1995-2004), period analysis demonstrated a greater difference than complete analysis (9.0 versus 3.9%). Subgroup analysis indicated that the survival improvement was determined by period analysis, and it was more pronounced for the age group,74 years and in Stages III-IV patients. Conclusions: We observed that period analysis demonstrates the most similar results to the actual observed survival and is, therefore, a useful method to derive precise cancer survival in gastric cancer. This information is useful to understand survival differences that are influenced by changing treatment strategy.
AB - Objective: To establish a comprehensive cancer treatment and prevention policy, data collection should be performed in a timely manner, and survival analysis needs to reflect changes in treatment strategy. Therefore, we introduced the concept of period analysis for gastric cancer, the most prevalent cancer in Korea. We estimated 5- and 10-year survival trend of gastric cancer, based on data from the Yonsei Cancer Center Tumor Registry between 1990 and 2004. Methods: We compared the differences in survival between cohort, complete and period analyses for two different periods, 1995-99 and 2000-04. Results: A total of 11 724 cases were included. The median age of cancer diagnosis gradually increased over time, and more patients were diagnosed with Stage I disease in recent years. In the basic comparison of three estimated analytic methods (cohort, complete and period), period analysis (45.8%) was most similar to the actual 5-year observed survival rate (48.5%), when compared with cohort (43.6%) and complete (44.8%) analyses. When we compared survival between different 10-year periods (1990-99 and 1995-2004), period analysis demonstrated a greater difference than complete analysis (9.0 versus 3.9%). Subgroup analysis indicated that the survival improvement was determined by period analysis, and it was more pronounced for the age group,74 years and in Stages III-IV patients. Conclusions: We observed that period analysis demonstrates the most similar results to the actual observed survival and is, therefore, a useful method to derive precise cancer survival in gastric cancer. This information is useful to understand survival differences that are influenced by changing treatment strategy.
UR - http://www.scopus.com/inward/record.url?scp=82955240722&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82955240722&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyr153
DO - 10.1093/jjco/hyr153
M3 - Article
C2 - 22128316
AN - SCOPUS:82955240722
SN - 0368-2811
VL - 41
SP - 1344
EP - 1350
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
IS - 12
M1 - hyr153
ER -